Modified recombinant human erythropoietin with potentially reduced immunogenicity.

Susantad, Thanutsorn; Fuangthong, Mayuree; Tharakaraman, Kannan; Tit-Oon, Phanthakarn; Ruchirawat, Mathuros; Sasisekharan, Ram

Susantad, Thanutsorn; Fuangthong, Mayuree; Tharakaraman, Kannan; Tit-Oon, Phanthakarn; Ruchirawat, Mathuros; Sasisekharan, Ram.

Affiliation

Susantad T; Program in Environmental Toxicology, Chulabhorn Graduate Institute, Bangkok, 10210, Thailand.
Fuangthong M; Translational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Tharakaraman K; Translational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Tit-Oon P; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Ruchirawat M; Translational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Sasisekharan R; Translational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand. mathuros@cri.or.th.

Sci Rep ; 11(1): 1491, 2021 01 15.

Article de En | MEDLINE | ID: mdl-33452310

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Érythropoïétine Limites: Humans Langue: En Journal: Sci Rep Année: 2021 Type de document: Article Pays d'affiliation: Thaïlande

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google